- $4.85bn
- $9.40bn
- $4.79bn
- 69
- 86
- 62
- 84
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 18.38 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.75 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.01 | ||
| EV to EBITDA | 15.72 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 1.38% | ||
| Return on Equity | -4.76% | ||
| Operating Margin | 3.38% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 3,412 | 3,765 | 3,768 | 4,146 | 4,791 | 5,005.23 | 5,287.61 | 4.87% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | -83.31 | n/a | n/a | n/a | +38.8 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 19th, 2020
- Public Since
- May 6th, 2022
- No. of Shareholders
- 4
- No. of Employees
- 13,500
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
New York Stock Exchange- Shares in Issue
- 353,364,741
- Address
- 520 Applewood Crescent, VAUGHAN, L4K 4B4
- Web
- https://ir.bausch.com/
- Phone
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for BLCO
Q1 2025 Bausch + Lomb Corp Earnings Release
Bausch + Lomb Corp Annual Shareholders Meeting
Bausch + Lomb Corp Annual Shareholders Meeting
Similar to BLCO
Abbott Laboratories
New York Stock Exchange
Agilent Technologies
New York Stock Exchange
Alcon AG
New York Stock Exchange
Artivion
New York Stock Exchange
Avanos Medical
New York Stock Exchange
FAQ
What is the Bausch + Lomb share price?
As of Today at 19:31 UTC, shares in Bausch + Lomb are trading at $13.73. This share price information is delayed by 15 minutes.
How has the Bausch + Lomb share price performed this year?
Shares in Bausch + Lomb last closed at $13.73 and the price had moved by -6.98% over the past 365 days. In terms of relative price strength the Bausch + Lomb share price has underperformed the S&P500 Index by -14.14% over the past year.
What are the analyst and broker recommendations for Bausch + Lomb?
The overall consensus recommendation for Bausch + Lomb is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Bausch + Lomb dividend yield?
Bausch + Lomb does not currently pay a dividend.
Does Bausch + Lomb pay a dividend?
Bausch + Lomb does not currently pay a dividend.
When does Bausch + Lomb next pay dividends?
Bausch + Lomb does not currently pay a dividend.
How do I buy Bausch + Lomb shares?
To buy shares in Bausch + Lomb you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Bausch + Lomb?
As of the previous close price of $13.73, shares in Bausch + Lomb had a market capitalisation of $4.85bn.
Where are Bausch + Lomb shares listed?
Here are the trading details for Bausch + Lomb:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: BLCO
What kind of share is Bausch + Lomb?
Based on an overall assessment of its quality, value and momentum Bausch + Lomb is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Bausch + Lomb share price forecast for 2025?
The analyst consensus target price for shares in Bausch + Lomb is $18.41. That is 34.09% above the last closing price of $13.73.
Analysts covering Bausch + Lomb currently have a consensus Earnings Per Share (EPS) forecast of $0.67 for the next financial year.
Find out moreWhat is the trend in the Bausch + Lomb share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bausch + Lomb. Over the past six months, its share price has underperformed the S&P500 Index by -29.27%.
As of the last closing price of $13.73, shares in Bausch + Lomb were trading -19.9% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Bausch + Lomb PE Ratio?
The Bausch + Lomb PE ratio based on its reported earnings over the past 12 months is 18.38. The shares last closed at $13.73.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Bausch + Lomb?
We do not have data on Bausch + Lomb's directors